Literature DB >> 1622415

Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma).

L Rudnicka1, S Majewski, M Blaszczyk, A Skiendzielewska, B Makiela, M Skopinska, S Jablonska.   

Abstract

OBJECTIVE: Perivascular infiltrates in skin, subcutaneous tissue, and internal organs are a characteristic feature of early systemic sclerosis (SSc). We studied the first step of migration of peripheral blood mononuclear cells (PBMC) through the vessel wall to the extravascular space, i.e., adhesion of PBMC to endothelial cells (EC), in patients with various forms of SSc (limited scleroderma, diffuse scleroderma, and the transitional form).
METHODS: Radioisotope-labeled patient PBMC were coincubated with umbilical cord EC in vitro, and the percentage adhesion was measured.
RESULTS: Adhesion of PBMC to EC was markedly decreased, while adhesion of isolated active rosette-forming cells (ARFC) was significantly increased, in SSc patients compared with healthy controls. Decreased adhesion of PBMC to EC was found to correlate with a diminished percentage of ARFC in the peripheral blood. Preincubation of PBMC from healthy donors with interleukin-2 (IL-2) enhanced their adhesion to EC, while preincubation of PBMC from SSc patients with this cytokine resulted in a decrease in adhesion in 10 of 14 individuals. IL-1, interferon-gamma, and transforming growth factor beta had no significant effect on adhesion of SSc patient PBMC to EC. Differences in adhesion of PBMC to EC among the SSc subgroups were not significant.
CONCLUSION: Our findings suggest that in SSc, activation of subpopulations of PBMC leads to their enhanced adhesion to vascular endothelium in vivo and to migration of these cells to the extravascular space, resulting in the elimination from the peripheral blood of those PBMC with high ability to adhere to EC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622415     DOI: 10.1002/art.1780350710

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

1.  Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis.

Authors:  H Ihn; S Sato; M Fujimoto; A Igarashi; N Yazawa; M Kubo; K Kikuchi; K Takehara; K Tamaki
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

2.  IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines.

Authors:  D Carvalho; C O Savage; C M Black; J D Pearson
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

3.  The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1.

Authors:  Bradley J Rabquer; Yong Hou; Francesco Del Galdo; G Kenneth Haines; Michele L Gerber; Sergio A Jimenez; James R Seibold; Alisa E Koch
Journal:  Rheumatology (Oxford)       Date:  2009-05-13       Impact factor: 7.580

Review 4.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

5.  Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion.

Authors:  Y Hou; B J Rabquer; M L Gerber; F Del Galdo; S A Jimenez; G K Haines; W G Barr; M C Massa; J R Seibold; A E Koch
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

Review 6.  The aetiopathogenesis of systemic sclerosis: thick skin--thin hypotheses. The Parkes Weber Lecture 1994.

Authors:  C M Black
Journal:  J R Coll Physicians Lond       Date:  1995 Mar-Apr

Review 7.  Kidney transplantation in systemic sclerosis: Advances in graft, disease, and patient outcome.

Authors:  Federica Maritati; Michele Provenzano; Sarah Lerario; Valeria Corradetti; Claudia Bini; Marco Busutti; Valeria Grandinetti; Vania Cuna; Gaetano La Manna; Giorgia Comai
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.